Jennison Associates LLC Immuno Gen, Inc. Transaction History

Jennison Associates LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 26, 2023	SELL	$3.67 - $4.92 $25.1 Million - $33.6 Million	-6,831,763 Reduced 74.74%	2,308,596 $8.87 Million
Q4 2022 Feb 09, 2023	BUY	$4.55 - $6.31 $13.4 Million - $18.6 Million	2,942,879 Added 47.49%	9,140,359 $45.3 Million
Q3 2022 Nov 01, 2022	BUY	$4.48 - $6.47 $27.8 Million - $40.1 Million	6,197,480 New	6,197,480 $29.6 Million
Q4 2019 Feb 07, 2020	SELL	$2.25 - $5.8 $360,031 - $928,081	-160,014 Closed	0 $0
Q3 2019 Nov 08, 2019	SELL	$2.22 - $3.39 $1.02 Million - $1.56 Million	-461,293 Reduced 74.25%	160,014 $387,000
Q2 2019 Aug 06, 2019	SELL	$1.8 - $3.3 $1.53 Million - $2.81 Million	-850,369 Reduced 57.78%	621,307 $0
Q1 2019 May 10, 2019	BUY	$2.41 - $5.91 $961,240 - $2.36 Million	398,855 Added 37.18%	1,471,676 $3.99 Million
Q4 2018 Feb 06, 2019	SELL	$3.94 - $9.7 $396,123 - $975,228	-100,539 Reduced 8.57%	1,072,821 $5.15 Million
Q3 2018 Nov 08, 2018	BUY	$8.6 - $11.26 $74,966 - $98,153	8,717 Added 0.75%	1,173,360 $11.1 Million
Q2 2018 Aug 02, 2018	BUY	$9.52 - $12.15 $11.1 Million - $14.2 Million	1,164,643 New	1,164,643 $11.3 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.